{"title":"CD19阴性弥漫性大b细胞淋巴瘤表现为白血病期","authors":"Thulasi Raman Ramalingam, Ragavi Uthayasuriyan, Vikram Prabhakar, Lakshman Vaidhyanathan","doi":"10.1002/cyto.b.22109","DOIUrl":null,"url":null,"abstract":"Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkins lymphoma affecting elderly individuals. It is an aggressive disease, but the outcomes have quite improved after the addition of monoclonal antibodies to the chemotherapy regimen. DLBCL in leukemic phase (L-DLBCL) is extremely rare compared with other mature B cell neoplasms. L-DLBCL can mimic acute lymphoblastic leukemia and immunophenotyping (IPT)","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"CD19 negative diffuse large B-cell lymphoma presenting in leukemic phase\",\"authors\":\"Thulasi Raman Ramalingam, Ragavi Uthayasuriyan, Vikram Prabhakar, Lakshman Vaidhyanathan\",\"doi\":\"10.1002/cyto.b.22109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkins lymphoma affecting elderly individuals. It is an aggressive disease, but the outcomes have quite improved after the addition of monoclonal antibodies to the chemotherapy regimen. DLBCL in leukemic phase (L-DLBCL) is extremely rare compared with other mature B cell neoplasms. L-DLBCL can mimic acute lymphoblastic leukemia and immunophenotyping (IPT)\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2022-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.22109\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.22109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
CD19 negative diffuse large B-cell lymphoma presenting in leukemic phase
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkins lymphoma affecting elderly individuals. It is an aggressive disease, but the outcomes have quite improved after the addition of monoclonal antibodies to the chemotherapy regimen. DLBCL in leukemic phase (L-DLBCL) is extremely rare compared with other mature B cell neoplasms. L-DLBCL can mimic acute lymphoblastic leukemia and immunophenotyping (IPT)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
